C91.02
Acute lymphoblastic leukemia, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Acute lymphoblastic leukemia (ALL) is a rapid-growing cancer that affects the blood and bone marrow, where blood cells are produced. When ALL reappears after treatment, it is referred to as a relapse. This condition requires careful medical evaluation and management. Knowing what relapse entails and how it is identified can help patients and their loved ones better understand the ongoing process of diagnosis and treatment.
Causes & Symptoms
Clinical Causes: Previous treatment failure or incomplete eradication of leukemia cells Genetic mutations within leukemia cells that confer resistance to therapy Underlying genetic predispositions increasing relapse risk Subclinical presence of residual leukemia cells that were undetectable initially Environmental factors or exposures that may influence disease progression
Key Symptoms: Persistent or recurring fatigue Unexplained fever or night sweats Frequent infections Easy bruising or bleeding Bone or joint pain Signs of anemia such as pale skin and shortness of breath Swelling or pain in the abdomen due to enlarged spleen or liver Lymph Node swelling
Diagnostic & Treatment
Diagnosis Path: The diagnosis of ALL relapse involves several steps, including blood tests and additional procedures. These help determine the presence and extent of leukemia recurrence: - **Complete blood count (CBC):** Identifies abnormal blood cell counts. - **Bone marrow biopsy:** Confirms the presence of leukemia cells in the marrow. - **Immunophenotyping:** Uses antibodies to identify specific markers on leukemia cells. - **Cytogenetic analysis:** Detects genetic changes that may suggest relapse. - **Imaging tests:** Such as ultrasound or CT scans to evaluate organ involvement. Regular follow-up and testing are crucial for early detection of relapse in patients previously treated for ALL.
Treatment Protocols: Managing a relapse of ALL involves a combination of strategies tailored to the patient's health profile and disease characteristics: - **Salvage chemotherapy:** Intensive chemotherapy aiming to eliminate leukemia cells. - **Targeted therapy:** Medications designed to attack specific genetic or molecular features of the leukemia cells. - **Immunotherapy:** Treatments such as monoclonal antibodies or CAR T-cell therapy to boost the immune response against leukemia. - **Bone marrow transplant:** In suitable cases, a hematopoietic stem cell transplant offers a potential cure by replacing the diseased marrow. - **Supportive care:** Includes transfusions, antibiotics, and growth factors to manage side effects and infections. Treatment plans are typically devised by a specialized medical team and may involve clinical trials exploring new therapies.
Clinical Advice & FAQs
Billing Guidance
Is C91.02 a billable ICD-10 code?
Yes, C91.02 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.02?
Clinical documentation must specify the nature of Acute lymphoblastic leukemia, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference